Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2020-11-10 4:58 pm Purchase |
2020-11-06 | 13G | CytomX Therapeutics, Inc. CTMX |
BIOTECHNOLOGY VALUE FUND L P | 4,626,411 10.000% |
1,437,463 (+45.08%) |
Filing History |
| 2020-11-09 5:26 pm Purchase |
2020-10-28 | 13G | MIRAGEN THERAPEUTICS INC MGEN |
BIOTECHNOLOGY VALUE FUND L P | 7,584,219 9.990% |
7,584,219 (New Position) |
Filing History |
| 2020-11-03 4:39 pm Sale |
2020-10-30 | 13G | BioLineRx Ltd. BLRX |
BIOTECHNOLOGY VALUE FUND L P | 148,671 1.900% |
-632,391 (-80.97%) |
Filing History |
| 2020-10-20 08:59 am Purchase |
2020-05-22 | 13G | ContraFect Corporation CFRX |
BIOTECHNOLOGY VALUE FUND L P | 36,361 9.990% |
36,361 (New Position) |
Filing History |
| 2020-10-13 5:18 pm Sale |
2020-10-09 | 13D | PHAXIAM Therapeutics S.A. PHXM |
BIOTECHNOLOGY VALUE FUND L P | 44,619 23.500% |
-857 (-1.88%) |
Filing History |
| 2020-10-09 5:20 pm Unchanged |
2020-10-07 | 13D | XOMA Corporation XOMA |
BIOTECHNOLOGY VALUE FUND L P | 4,182,243 38.000% |
0 (Unchanged) |
Filing History |
| 2020-10-08 5:26 pm Purchase |
2020-10-06 | 13D | FIVE PRIME THERAPEUTICS INC FPRX |
BIOTECHNOLOGY VALUE FUND L P | 8,364,353 22.800% |
581,352 (+7.47%) |
Filing History |
| 2020-10-05 5:26 pm Purchase |
2020-10-01 | 13G | NOVUS THERAPEUTICS INC NVUS |
BIOTECHNOLOGY VALUE FUND L P | 195,326 15.600% |
195,326 (New Position) |
Filing History |
| 2020-09-23 5:28 pm Purchase |
2020-09-21 | 13D | XOMA Corporation XOMA |
BIOTECHNOLOGY VALUE FUND L P | 4,182,243 38.000% |
156,086 (+3.88%) |
Filing History |
| 2020-08-25 5:27 pm Purchase |
2020-08-21 | 13D | Kymera Therapeutics, Inc. KYMR |
BIOTECHNOLOGY VALUE FUND L P | 2,630,662 5.900% |
2,630,662 (New Position) |
Filing History |
| 2020-08-25 12:32 pm Unchanged |
2020-08-25 | 13D | PRINCIPIA BIOPHARMA INC PRNB |
BIOTECHNOLOGY VALUE FUND L P | 5,231,900 15.700% |
0 (Unchanged) |
Filing History |
| 2020-08-19 1:49 pm Purchase |
2020-08-17 | 13G | PRINCIPIA BIOPHARMA INC PRNB |
BIOTECHNOLOGY VALUE FUND L P | 5,231,900 15.700% |
3,515,166 (+204.76%) |
Filing History |